The interaction of nucleosides with the glucose carrier of human erythrocytes was examined by studying the effect of nucleosides on reversible cytochalasin B-binding activity and glucose transport. Adenosine, inosine and thymidine were more potent inhibitors of cytochalasin B binding to human erythrocyte membranes than was D-glucose [IC50 (concentration causing 50 % inhibition) values of 10, 24, 28 and 38 mm respectively]. Moreover, low concentrations of thymidine and adenosine inhibited D-glucose-sensitive cytochalasin B binding in an apparently competitive manner. Thymidine, a nucleoside not metabolized by human erythrocytes, inhibited glucose influx by intact cells with an IC50 value of 9 mm when preincubated with the erythrocytes. In contrast, thymidine was an order of magnitude less potent as an inhibitor of glucose influx when added simultaneously with the radioactive glucose. Consistent with this finding was the demonstration that glucose influx by inside-out vesicles prepared from human erythrocytes was more susceptible to thymidine inhibition than glucose influx by right-side-out vesicles. These data, together with previous suggestions that cytochalasin B binds to the glucose carrier at the inner face of the membrane, indicate that nucleosides are capable of inhibiting glucose-transport activity by interacting at the cytoplasmic surface of the glucose transporter. Nucleosides may also exhibit a low-affinity interaction at the extracellular face of the glucose transporter.
INTRODUCTION
Nucleosides and glucose cross the plasma membrane of human erythrocytes by functionally similar systems. Kinetic studies of nucleoside transport by human erythrocytes from fresh blood have demonstrated the presence of a kinetically symmetrical carrier with properties consistent with a simple carrier model [1, 2] . In contrast, the glucose transporter of human erythrocytes is kinetically asymmetric, the extent of which decreases as the temperature increases, such that at 37°C both Km and Vm.ax for zero-trans influx and effilux are similar [3] [4] [5] . Interestingly, the kinetic parameters obtained by using erythrocytes from outdated stored blood are significantly different from those determined with cells from fresh blood for both transport systems [1, 3] . A comparison of the effects of thiol reagents and trypsin on nucleoside-and glucose-transport activity in intact erythrocytes, inside-out vesicles and disrupted membranes has provided evidence that both transporters exhibit chemical asymmetry [6] [7] [8] [9] . Also, both transporters can be selectively inhibited by potent inhibitors that bind reversibly. Nucleoside transport is inhibited by nitrobenzylthioinosine (NBMPR) (apparent Kd 0.1-1.0 nM, I04 binding sites/cell), and glucose transport is blocked by cytochalasin B (apparent K1 0.1 /tM, 2 x 105 binding sites/cell) [10] [11] [12] . At the molecular level, both transporters have been demonstrated to be 'band-4.5' glycoproteins (apparent Mr 65 000-45 000) that co-purify after chromatography and electrophoresis [11, [13] [14] [15] . Nevertheless, the glucose and nucleoside transporters in erythrocytes are functionally distinct. For example, adult pigs possess a functional nucleoside-translocation mechanism, but are impermeable to sugars [16, 17] . Inter- estingly, plasma inosine has been demonstrated to be the major physiological energy source for adult pig erythrocytes [18, 19] .
A recent study [20] has demonstrated that the nucleoside 8-azidoadenosine, which is a permeant for the human erythrocyte nucleoside transporter, covalently labels the glucose transporter after exposure to u.v. light. This result, together with the previously known similarities of the two carriers, raises the possibility that nucleosides can interact with the glucose transporter. In the present study, the interaction of nucleosides with the glucose carrier was investigated by studying the effect of nucleosides on both reversible cytochalasin B-binding activity and glucose transport. It is established that nucleosides can interact with a greater affinity with the cytosolic face of the glucose carrier than with the extracellular face. A preliminary report of this study has been published [21] . Cell, vesicles and membrane preparation Fresh human blood was collected into heparin and the erythrocytes washed three times with a medium containing 140 mM-NaCl, 5 mM-KCl, 20 mM-Tris/HCl, pH 7.4 at 22°C, 2 mM-MgCl2 and 0.1 mM-EDTA (disodium salt). The buffy coat was discarded. Erythrocyte ghosts were prepared by osmotic lysis by the method of Dodge et al. [22] . Protein-depleted membranes were prepared from erythrocyte ghosts by using 0.1 mm-EDTA, pH 11.2, as described previously [13] , and resuspended in 50 mM-Tris/HCl, pH 7.4.
MATERIALS AND METHODS
Inside-out vesicles were prepared by the method of Steck & Kant [23] as modified by Macintyre [24] . Briefly, 4 ml of ghost membranes suspended in 5 mM-sodium phosphate, pH 8.0, at 3 mg of protein/ml, were diluted with 136 ml of prewarmed (35°C) vesiculation medium containing 0.5 mM-sodium phosphate and 0.5 mm-EGTA, pH 8.4. This suspension was incubated for 15 min at 35°C, and the membranes were recovered by centrifugation (30000 g for 20 min). The membranes were resuspended in 4 ml of ice-cold vesiculation medium and then homogenized by using a 5 ml syringe and a no. 27-gauge needle to complete vesiculation. The vesicle suspension was diluted to 8 ml, and 2 ml aliquots were layered on to 3 ml of Dextran T-70 barrier solution [4.5 % (w/v) Dextran T-70 in 0.5 mM-sodium phosphate, pH 8 .0] in a 5 ml Beckman SW55 centrifuge tube and centrifuged at 100000 g for 1 h at 4 'C. Sealed inside-out vesicles were recovered from the barrier interface and washed twice in ice-cold 5 mM-sodium phosphate, pH 8.0. The final vesicle pellet was resuspended to a protein concentration of 2-4 mg of protein/ml and used immediately.
Right-side-out vesicles were also prepared by the method of Steck & Kant [23] . Ghost membranes (5 ml) were diluted to 120 ml with 0.5 mM-sodium phosphate, pH 8.0, and gently stirred at 4 'C for 30 min. A portion of 200 mM-MgSO4 was added to the suspension to give a final concentration of0.1 mM-MgSO4 and the membranes pelleted by centrifugation (30000 g for 1 h). The membrane pellet was resuspended in 4 ml of 0.1 mM-MgSO4/ 0.5 mM-sodium phosphate, pH 8.0, and homogenized as described for the inside-out vesicles. The homogenized suspension was diluted to 8 ml, and 2 ml aliquots were layered on to 3 ml of 4.5 % (w/v) Dextran T-70. The sealed right-side-out vesicles were recovered after centrifugation by using the same procedure as described above, washed twice, and resuspended in sodium phosphate, pH 8.0 (2-4 mg of protein/ml).
Vesicle sidedness was established by measuring the activity of acetylcholinesterase, a marker enzyme for the extracellular membrane surface, and glyceraldehyde-3-phosphate dehydrogenase, a marker enzyme for the intracellular membrane surface, in the presence and absence of Triton X-100 [23, 25] . The Kinetic constants of D-glucose-sensitive cytochalasin B binding were determined both by non-linear least-squares fit of a single-site-saturation isotherm and by Scatchard analyses using a weighted-linear-regression computer program [37] .
Nucleoside transport
The initial rates of NBMPR-sensitive uridine uptake (O.1 mm extracellular concentration, 5 s) at 22°C by intact erythrocytes were measured by an oil-stop procedure employing n-dibutyl phthalate [29] . The ability of sugars to cause the inward countertransport of radioactively labelled uridine was measured as previously described [30] . Glucose transport For intact erythrocytes, initial rates of cytochalasin Bsensitive glucose uptake (5 mm extracellular concentration, 5 s incubation) were measured by a modified procedure of that used to estimate uridine-transport rates [29] . Briefly, 0. NaCl/ I, #m-HgCl2/ 1.25 mm K/ I 00,#m-phloretin) [3] layered on top of 0.5 ml of ice-cold n-dibutyl phthalate in microcentrifuge tubes. The tubes were immediately centrifuged (12000 g, 15 s) and the radioactivity associated with the cell pellet determined as described previously [29] . Blank values (radioactivity that became associated with the cells during an uptake interval of zero time) were obtained by processing cell samples simultaneously exposed to radioactively labelled glucose and 10 ,sM-cytochalasin B at 1 'C. Transport rates were calculated after subtraction of the blank (typically 20 
RESULTS

Cytochalasin B binding
The effects of various concentrations of nucleosides and sugars on [3H]cytochalasin B binding to alkalistripped human erythrocyte ghosts are shown in Fig. 1 . Alkali-stripped ghosts were used because these membranes retain D-glucose-sensitive cytochalasin B-binding sites and most of the high-affinity cytochalasin B-binding sites not displaceable by high concentrations of Dglucose are absent [12, 31] . In agreement with previous results [32] , D-glucose was shown to displace > 90 % of the saturable cytochalasin B-binding sites, with an IC50 value of 38 mM. L-Glucose was much less effective (< 10 % inhibition at 600 mM-L-glucose). Fig. 1 
D-Glucose transport activity
In a complementary approach, the effect of thymidine, a non-metabolized nucleoside in human erythrocytes, on D-glucose transport (extracellular concentration 5 mM) was investigated. When thymidine and [3H}glucose were added simultaneously, thymidine inhibited glucose influx when present at high concentrations (approx. 500 inhibition at 90 mM-thymidine; see Fig. 3 ). In contrast, preincubation of cells with thymidine for 2 h at 37°C to allow equilibration, followed by rapid removal of the extracellular thymidine so that most of the thymidine was only present inside the erythrocyte, resulted in marked inhibition of glucose influx (IC50 value of 9 mM; Fig. 3 ). These results suggest that thymidine is interacting at both the extracellular and the cytoplasmic surface of the glucose carrier, with a relatively greater affinity of interaction with the cytoplasmic face than with the extracellular face. An alternative explanation, namely that the extracellular thymidine is inhibiting glucose transport because of intracellular accumulation of thymidine during the 5 s incubation period, is not valid. The maximum intracellular thymidine concentrations achievable after 5 s at extracellular thymidine concentrations sufficient to saturate the nucleoside carrier are at the most 0.2 mm [1, 2] , a concentration that produces no significant inhibition of glucose transport.
Moreover, the addition of 10 /iM-NBMPR to inhibit thymidine influx had no effect on the ability of extracellular thymidine to compete with glucose for entry (results not shown). Additional experiments demonstrated that NBMPR had no effect on [3H]glucose influx by erythrocytes, even at high concentrations such as 10 /M, a concentration 104-fold greater than the K, value for inhibition of nucleoside transport [11] . Cytochalasin E (1O ,M) was also ineffective (<5 % inhibition). In contrast, cytochalasin B, as expected, inhibited the zerotrans influx of 5 mM-glucose with an IC50 value of 0.6 /tM.
As a further test of the greater affinity of nucleosides with the cytosolic face of the glucose carrier, the ability of thymidine to inhibit glucose transport in membrane vesicles prepared from human erythrocyte ghosts was investigated. Fig. 4 shows the time course of glucose uptake (extravesicular concentration 5 mM) by inside-out vesicles at 15°C in the presence and absence of cytochalasin B (10 /tM). Inside-out vesicles are capable of a rapid glucose uptake that was sensitive to inhibition by cytochalasin B; the residual glucose uptake in the presence of cytochalasin B was 7 subsequent studies, estimates of initial glucose-transport rates by both vesicle preparations were determined with a 5 s incubation period. Fig. 5 compares the effect of thymidine on glucose uptake by inside-out and right-side-out vesicles. Glucose uptake by inside-out vesicles compared with right-side out vesicles was 2-fold more susceptible to thymidine inhibition under identical experimental conditions, supporting the suggestion that thymidine has a greater affinity for the glucose transporter at the cytosolic face. The difference between thymidine inhibition of glucose transport in inside-out versus right-side-out vesicles is much smaller than that apparent for intracellular versus extracellular nucleoside in the experiment of Fig. 3 . However, it should be noted that the inside-out vesicles are less pure (70-80 %) than the right-side-out vesicles (90-96 %), and thus the true inhibition curve in Fig. 5 for a 100 % preparation of inside-out vesicles is likely to be shifted to the left, thereby increasing the difference in transport inhibition between inside-out and right-sideout vesicles.
To investigate further the mechanism of inhibition of glucose transport by thymidine and the possibility that thymidine may be a poor permeant for the glucose transporter, the countertransport of [3H]glucose after preloading human erythrocytes with thymidine and Dgalactose was compared (Fig. 6) [3H]uridine compared with the control (Fig. 6) (Fig. 6) . 
DISCUSSION
This study demonstrated that nucleosides inhibited Dglucose-sensitive cytochalasin B binding and D-glucose transport in human erythrocytes. Uptake of glucose by human erythrocytes was approx. 10-fold more sensitive to inhibition by thymidine when the nucleoside was mainly present at the cytoplasmic, as opposed to the extracellular, surface. Consistent with this finding was the demonstration that glucose uptake by inside-out membrane vesicles was also more susceptible to inhibition by thymidine than when a vesicle preparation consisting of right-side-out membrane vesicles was used. In addition adenosine, inosine and thymidine and, to a lesser extent, uridine, were shown to inhibit D-glucose-sensitive cytochalasin B binding. However, the mode of inhibition of cytochalasin B binding by nucleosides is complex. At low concentrations (less than 7 mm and 25 mm for adenosine and thymidine respectively), adenosine and thymidine acted as apparent competitive inhibitors of D-glucosesensitive cytochalasin B binding, with Ki values of 3.0 and 5.0 mm respectively. In comparison, the Ki value for Dglucose inhibition of cytochalasin B binding to human erythrocyte membranes has been shown previously to range from 30 to 60 mm [12, 32, 34] . Higher concentrations of adenosine resulted in a mixed type of inhibition, suggesting that adenosine is also interacting with the erythrocyte membrane at a site distinct from the highaffinity cytochalasin B-binding site. Cytochalasin B has been postulated to bind with high affinity (apparent Kd 0.1 LM) to the glucose carrier at the inner face of the membrane [35, 36] . Thus the findings that (i) nucleosides are more potent inhibitors of glucose transport when present at the cytoplasmic surface as opposed to the extracellular surface and (ii) low concentrations of adenosine and thymidine inhibit D-glucose-sensitive cytochalasin B binding in a competitive manner suggest that the nucleosides are acting with greater affinity at the inner surface of the membrane than at the extracellular face. Cytochalasin B and nucleosides might bind to the same specific site, or alternatively to different sites, causing conformational changes that prevent one another from binding. The present data do not exclude the possibility that nucleosides also interact with low affinity at the extracellular face of the glucose transporter. Extracellular nucleosides are capable of inhibiting glucose transport (Figs. 3 and 5) , and the finding that high concentrations of adenosine result in mixed inhibition ofcytochalasin B binding may be due to adenosine binding to the extracellular surface with low affinity. The failure of thymidine to cause the countertransport of Dglucose suggests that thymidine is not a permeant for the glucose carrier.
The specific inhibitor of nucleoside transport, NBMPR, had no effect on either glucose uptake or highaffinity cytochalasin B binding. Similarly, high concentrations of D-and L-glucose (500 mM) and cytochalasin B and E (25 /LM) also failed to inhibit NBMPR binding by human erythrocyte membranes. Glucose and galactose were also without effect on the influx of uridine by human erythrocytes when present at either the inner or outer membrane surface. In contrast, various cytochalasin derivatives were able to inhibit uridine influx in an apparently selective manner. Cytochalasin E was without effect, but dihydrocytochalasin B caused 50% inhibition of uridine influx at concentrations less than 5/M, a concentration that had little effect on glucose influx. Cytochalasin B also inhibited uridine influx, but with a sensitivity of about 100-fold less than that observed for inhibition ofD-glucose uptake. These results further support the use of NBMPR and cytochalasin B as specific probes of the NBMPR-sensitive facilitateddiffusion nucleoside transporter and the facilitated-diffusion glucose carrier respectively. However, high concentrations of cytochalasin B (> S,UM) should be avoided, because at these concentrations inhibitory effects of cytochalasin B on the nucleoside carrier are apparent.
In conclusion, the present results demonstrate that nucleosides can interact with the glucose transporter of human erythrocytes at the inner face of the membrane. This interaction is unlikely to have any physiological significance, because the plasma concentration of nucleosides, and hence the maximum intracellular concentration in the erythrocyte, do not exceed 10 ,UM [19, 38] , a value that is 300-2800-fold less than the IC50 values for nucleoside inhibition of glucose transport. The present results further indicate the structural similarities between the glucose and nucleoside transporters in human erythrocytes.
